The GLP-1 era is reshaping more than weight. Here's what the next-generation pipeline actually says.
STEP, SURMOUNT, SELECT, FLOW. The mechanism, the trial endpoints, the lean-mass critique taken seriously, and what's coming behind tirzepatide — without the wellness fog and without the pharma-evangelism.
[Wilding 2021]
pointing to the references list at the bottom. Where evidence is preliminary,
we say so. Where mechanism is speculative, we say so. Where it's marketing,
we name it.
Why this matters now
Semaglutide and tirzepatide are not weight-loss drugs that happen to have cardiometabolic effects. They are cardiometabolic drugs that happen to drive weight loss. The order matters because it predicts which patients benefit, which trials will read out positive, and which next-generation candidates will displace the incumbents.
In 2024, the SELECT trial showed a 20% reduction in major adverse cardiovascular events in non-diabetic patients with obesity and prior cardiac disease [Lincoff 2023]. In 2024, the FLOW trial was stopped early for benefit on kidney outcomes [Perkovic 2024]. Neither endpoint is a surrogate. Both moved practice.
This article is not a recommendation to take semaglutide or tirzepatide. It is a framework for reading the trial data the way a thoughtful clinician would — and a tiered protocol for people who, after reading it, want to talk to one.
Mechanism: incretins, the gut–brain axis, and why "appetite drug" undersells it
GLP-1 (glucagon-like peptide-1) is an incretin hormone — a peptide secreted by intestinal L-cells in response to nutrient ingestion that amplifies glucose-dependent insulin secretion [Drucker 2018]. Native GLP-1 has a half-life of roughly 2 minutes, which is why pharmaceutical GLP-1 receptor agonists (GLP-1 RAs) are engineered for resistance to the DPP-4 enzyme that degrades the native peptide.
Semaglutide is once-weekly because its acylation to an albumin-binding fatty-acid side chain extends the half-life to roughly 165 hours [Lau 2015]. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism to GLP-1 agonism in a single molecule — and the additive effect on both glycemia and weight has been consistently larger than GLP-1 alone in head-to-head data [Frias 2021].
"Appetite drug" undersells the mechanism. The same receptors that suppress appetite also slow gastric emptying, improve insulin sensitivity, reduce hepatic glucose output, and act centrally on reward pathways implicated in addiction.
What the receptor actually does
The GLP-1 receptor is a Gαs-coupled GPCR expressed in:
- Pancreatic β-cells — glucose-dependent insulin secretion
- Pancreatic α-cells — glucagon suppression
- Gastric smooth muscle — delayed gastric emptying
- Hypothalamic neurons (arcuate, PVN) — satiety signaling
- Brainstem (NTS, area postrema) — nausea, the dose-limiting side effect
- Cardiac and vascular endothelium — likely mechanism of MACE reduction
- Renal afferent arterioles — likely mechanism of eGFR preservation
Reading those tissues, the cardio-renal endpoints are not a surprise. They are what you would predict from the receptor map.
The trial landscape: STEP, SURMOUNT, SELECT, FLOW
STEP — semaglutide for weight
The STEP program (5 phase-3 trials) tested semaglutide 2.4 mg weekly in people with obesity or overweight + comorbidity. STEP 1 reported a mean weight change of −14.9% versus −2.4% on placebo at 68 weeks [Wilding 2021]. That is not a margin you see in lifestyle-arm trials.
SURMOUNT — tirzepatide for weight
SURMOUNT-1 reported −20.9% at the 15 mg dose at 72 weeks [Jastreboff 2022]. SURMOUNT-2 (in people with type 2 diabetes) showed −14.7% — diabetes blunts response, as it does for semaglutide too.
SELECT — cardiovascular outcomes
SELECT enrolled 17,604 non-diabetic adults with obesity and established cardiovascular disease. Semaglutide 2.4 mg reduced the primary composite of cardiovascular death, non-fatal MI, or non-fatal stroke by 20% (HR 0.80, 95% CI 0.72–0.90) over a median 39.8 months [Lincoff 2023]. This is what hard-endpoint trial data looks like.
FLOW — renal outcomes
FLOW tested semaglutide 1.0 mg in patients with type 2 diabetes and chronic kidney disease. The trial was stopped early for efficacy. Risk of the primary composite (kidney failure, ≥50% eGFR decline, renal or cardiovascular death) dropped 24% [Perkovic 2024].
SELECT and FLOW transform the conversation. We are no longer asking whether the weight loss is durable enough to justify the cost. We are asking whether GLP-1 RAs should be considered cardio-renal protective agents in their own right — which is a different drug class entirely.
The lean-mass critique, taken seriously
The most credible critique of GLP-1 weight loss is that roughly 25–40% of the lost mass is fat-free mass, including skeletal muscle [Wilding 2021]. This is comparable to caloric restriction diets — but the absolute amount of muscle lost is larger because the total weight loss is larger.
Three things change the math:
- Protein floor. 1.6–2.2 g/kg of reference body weight appears to be the threshold below which sarcopenia accelerates in caloric deficit [Phillips 2016].
- Resistance training. Two to three sessions per week of progressive overload preserves the majority of lean mass during weight loss in non-pharmacologic trials and almost certainly applies here, though dedicated RCTs in GLP-1 cohorts are limited.
- Rate. Targeting ~0.5–1% body weight per week, rather than maximum tolerated dose, preserves more lean mass.
The next-generation pipeline
Retatrutide (Eli Lilly) is a GLP-1 / GIP / glucagon triple agonist. Phase 2 reported −24.2% weight loss at 12 mg at 48 weeks [Jastreboff 2023]. Phase 3 (TRIUMPH) is enrolling.
CagriSema (Novo Nordisk) combines cagrilintide (amylin analog) with semaglutide. REDEFINE-1 reported −22.7% — below the company's pre-trial target — and the stock punished the readout accordingly. The drug is still clinically meaningful, just below the bar Novo set.
Orforglipron (Eli Lilly) is a non-peptide, orally bioavailable small-molecule GLP-1 RA. ACHIEVE-1 reported HbA1c reductions comparable to injectable GLP-1s [Wharton 2023]. If approved at scale, an oral GLP-1 changes the access and cost picture substantially.
A tiered framework for thinking about it
We do not write protocols on this site. We write frameworks that you take to a clinician. With that established:
Establish protein floor (≥1.6 g/kg). Two resistance sessions weekly for 8+ weeks. Baseline labs (HbA1c, fasting insulin, lipids, eGFR). If your BMI is <30 with no metabolic comorbidity, the trial data does not transplant cleanly — start here, not at a prescription.
Indicated: BMI ≥30, or ≥27 with comorbidity. Standard titration (semaglutide 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, monthly steps). Maintain protein and resistance training throughout. Re-pull metabolic labs at 12 and 24 weeks.
Microdose protocols for metabolic-rather-than-weight indications. Triple-agonist trials when enrolling. Stack discussions (with cardiologist or endocrinologist) for cardio-renal protection. Compounded versions only from 503A pharmacies, with the regulatory risk explicitly understood.
We will not tell you to compound. We will not tell you to microdose. We will not tell you to source peptides from research-chemical sites. Every tier here assumes a clinician relationship. If you don't have one, that's the first protocol — not the last.
References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391:109-121.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
- Wharton S, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877-888.
- Phillips SM, Chevalier S, Leidy HJ. Protein requirements beyond the RDA. Appl Physiol Nutr Metab. 2016;41(5):565-572.